InsidersTradesSigma
Total declarations
Companies
▲ Purchases (29 ops.)
▼ Sales (0 ops.)
Insider track record
CEODisclosed buys
29
Disclosed sells
0
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Explore the complete record of transactions filed by Hayes Anthony, Chief Executive Officer. Director active across 2 companies, notably AIkido Pharma Inc.. Cumulatively, 37 disclosures have been recorded. Split: 29 buys · 0 sell. Total volume traded: €962k. Activity tracked since 3 May 2021. The latest transaction was filed on 8 December 2025 (Acquisition). Regulator: SEC (Form 4). All data is free.
Companies and markets linked to Hayes Anthony
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations37 total
250,000 sharesCommon StockSEC:0001213900-26-082271:0
3,000,000 sharesCommon StockSEC:0001213900-26-033790:0
23,000 shares@ US$3.871916.8% of flowCommon StockSEC:0001213900-25-119861:0
Canonical exit: 8 Mar 2026 (T+90)
23,000 shares@ US$3.871916.8% of flowCommon StockSEC:0001213900-25-120286:0
Canonical exit: 8 Mar 2026 (T+90)
15,000 sharesCommon StockSEC:0001213900-25-040168:0
154,559 sharesCommon StockSEC:0001013762-25-002158:0
500,000 sharesCommon StockSEC:0001213900-25-015820:0
288,184 sharesCommon StockSEC:0001213900-25-012975:0
Canonical exit: 11 May 2025 (T+90)
309,118 sharesCommon StockSEC:0001213900-25-000790:0
154,559 sharesCommon StockSEC:0001213900-24-052468:0
1,158 shares@ US$2.250.8% of flowCommon StockSEC:0001213900-24-048446:0
Canonical exit: 27 Aug 2024 (T+90)
3,944 shares@ US$2.62153.2% of flowCommon StockSEC:0001213900-24-031175:0
Canonical exit: 3 Jul 2024 (T+90)
70,000 shares@ US$2.002442.2% of flowCommon StockSEC:0001213900-23-097830:0
Canonical exit: 19 Mar 2024 (T+90)
2,000 shares@ US$2.00121.2% of flowCommon StockSEC:0001213900-23-095707:0
Canonical exit: 11 Mar 2024 (T+90)
1,323 shares@ US$2.08990.8% of flowCommon StockSEC:0001213900-23-090218:0
Canonical exit: 20 Feb 2024 (T+90)
2,500 shares@ US$1.96631.5% of flowCommon StockSEC:0001213900-23-088462:0
Canonical exit: 14 Feb 2024 (T+90)
2,500 shares@ US$1.92991.5% of flowCommon StockSEC:0001213900-23-087634:0
Canonical exit: 12 Feb 2024 (T+90)
7,500 shares@ US$2.499611.9% of flowCommon StockSEC:0001213900-23-078533:0
Canonical exit: 19 Dec 2023 (T+90)
2,000 shares@ US$2.74683.2% of flowCommon StockSEC:0001213900-23-077016:0
Canonical exit: 12 Dec 2023 (T+90)
2,000 shares@ US$2.85891.7% of flowCommon StockSEC:0001213900-23-070962:0
Canonical exit: 21 Nov 2023 (T+90)
2,000 shares@ US$2.93991.8% of flowCommon StockSEC:0001213900-23-068954:0
Canonical exit: 14 Nov 2023 (T+90)
1,319 shares@ US$2.87461.2% of flowCommon StockSEC:0001213900-23-049251:0
Canonical exit: 12 Sept 2023 (T+90)
506 shares@ US$2.88590.4% of flowCommon StockSEC:0001213900-23-048915:0
Canonical exit: 11 Sept 2023 (T+90)
2,000 shares@ US$2.751.7% of flowCommon StockSEC:0001213900-23-042860:0
Canonical exit: 22 Aug 2023 (T+90)
2,000 shares@ US$2.76891.7% of flowCommon StockSEC:0001213900-23-040988:0
Canonical exit: 15 Aug 2023 (T+90)
25 of 37 declarations
About Hayes Anthony
Hayes Anthony is Directeur Général and has filed 36 disclosures in total. In the 36 recent filings available, all acquisitions, purchases total EUR 961791 and sales total EUR 0, over the period from 2021-05-04 to 2026-03-24. These filings concern AIkido Pharma Inc. and Dominari Holdings Inc.
